Quick Search / Select a Section

Surrey Cancer Research Institute Seminar Archive

2019   2018  2017  2016        2015        2014


Professor Sarah Blagden, Department of Oncology, University of Oxford Cancer & Haematology Centre, Churchill Hospital
RBPs, the next frontier in cancer therapeutics
4pm Wednesday 6th March 2019
Room B1, The Education Centre, RSCH



ttps://www.oncology.ox.ac.uk/research/sarah-blagden https://www.oncology.ox.ac.uk/research/sarah-blagden  Dr Clare Gilson, Royal Surrey County Hospital, Guildford

 STAMPEDE Prostate Cancer study - How can we best select treatments for men presenting with metastatic castrate sensitive prostate cancer?
4pm Wednesday 6th February 2019
Room B1, The Education Centre, RSCH



Professor Emma Hall, The Institute of Cancer Research
Trialling technologies - designing and delivering radiotherapy clinical trials
4pm Wednesday 3rd October 2018
Room B2, The Education Centre, RSCH
Professor Christian Ottensmeier, University of Southampton
Genomic assessment of immune cells to understand the effect of immunotherapy
4pm Monday 24th September 2018
Room B2, The Education Centre, RSCH
Dr  Rebecca Kristeleit, University College London Hospital
Drug Development at UCL/UCLH: Rucaparib and other stories
4pm Wednesday 9th May 2018
Room B1, The Education Centre, RSCH
Dr  Debashis Sarker, Kings College, London
Implementing precision medicine in the clinic - myths and reality
4pm Wednesday 24th January 2018
Room B1, The Education Centre, RSCH



Dr  Marco Gerlinger, The Institute of Cancer Research, London
Tracking and targeting heterogeneous and evolving cancers
4pm Wednesday 29th November 2017
Room B1, The Education Centre, RSCH
Rachel Salisbury PhD, Medical Scientific Liaison Officer, Cancer - Roche
Introduction to Immunotherapy
4pm Monday 9th October 2017
Room B1, The Education Centre, RSCH

An overview of immunology and the science behind the cancer immunotherapy agents. The session will cover a background to the immune system and the cancer immunity cycle before discussing how cancer immunotherapies work and the PD1/PDL1 pathway 

Dr Yen-Ching Chang, University College Hospital, London
Proton Beam Therapy: Current and Future Provision
4pm Thursday 29 June 2017
Room B2, The Education Centre, RSCH
Professor Robert Jones, Professor of Clinical Cancer Research at the University of Glasgow
Urothelial cancer: chemotherapy, precision medicine or immuno-oncology
4pm Thursday 4 May 2017
Room B1, The Education Centre, RSCH




Professor Andrea Rockall
Professor of Radiology
Imperial College Healthcare NHS Trust

Imaging the silent killer: MRI in management of ovarian cancer
4pm Thursday 8th December 2016
Room B2, The Education Centre, RSCH




Professor Michael Brada
Department of Radiation Oncology
University of Liverpool

Brain metastases:  changing landscape in research & treatment
4pm Thursday 17th November 2016
Room B1, The Education Centre, RSCH




Dr Mieke Van Hemelrijck
Senior Lecturer in Cancer Epidemiology, Head of Cancer Epidemiology Group, Division of Cancer Studies
King's College London

Metabolic syndrome and prostate cancer: from biomarker studies to interventions
4pm Friday 21st October 2016
Room B2, The Education Centre, RSCH




Professor Andrew Tutt
Head of Division of Breast Cancer Research and Director of Breast Cancer Now's Research centre at the ICR
Targeting DNA repair deficiencies and genome instability in breast cancers

4pm Friday 30th September 2016
Room B2, The Education Centre, RSCH




Dr Loren Mell, MD
School of Medicine
University of Califonia, San Diego

Advances in image-guided radiation therapy for cervical cancer
9.30am Thursday 21st July 2016
Room B2, The Education Centre, RSCH




Dr Udai Banerji
Drug Development Unit, Division of Cancer Therapeutics, Division of Clinical Studies
The Institute of Cancer Research, Sutton

Critical biological questions in early phase clinical trials
4pm Thursday 5th May 2016
Room B1, The Education Centre, RSCH

The pharmacological audit trail is a set of scientific questions posed in early phase clinical trials.  These questions govern crucial go/no-go decisions in drug development and influence the way novel anticancer drugs are developed.




Professor Nick R Lemoine
BCI Director, Barts Cancer Institute - CR-UK Centre of Excellence
Queen Mary University of London

Viro-Immunotherapy for Pancreatic Cancer: making the untreatable curable and preventable?
4pm Thursday 14th April 2016
Room B1, The Education Centre, RSCH

Oncolytic virotherapy is a promising modality for the treatment of cancer, but the long-term outcomes of using viral agents alone in a clinical setting have been disappointing. Improved understanding of the interaction between the molecular mechanisms driving cancer and viral biology has enabled potential stratification of patients for individualised selection of viral agents. Increasing sophistication of genetic engineering of viral genomes has delivered both safe and more potent viruses, and combination approaches using different classes of viruses have produced cure in a range of preclinical models of pancreatic and other challenging cancer types. Modulation of the immune system using virally delivered cytokines and chemokine as well combination with small molecules and checkpoint inhibitors appears to offer the prospect of cure of disseminated disease and the possibility of prevention in at risk individuals.




Dr Sian Henson
Senior lecturer, Centre for Microvascular Research, William Harvey Research Institute
Queen Mary University of London

mTOR-independent regulation of senescent human CD8+ T cells
4pm Thursday 17th March 2016
05PGM01, Leggett Building, University of Surrey

Ageing is accompanied by alterations to T cell immunity and also by a low-grade chronic inflammatory state termed inflammageing. The significance of these phenomena is highlighted by baseline inflammation being a predictor of earlier mortality. As T cells age they lose proliferative capacity but they secrete high levels of pro-inflammatory cytokines and show potent cytotoxic activity. The maintenance of an inflammatory state is an energy-intensive process involving a switch from resting metabolic requirements to a highly active state which enables the production of host defense factors. Dr Henson will discuss how senescent T cells use non-canonical pathways to regulate their energy requirements. 




 Dr Paul Nathan, MBBS, PhD, FRCP
Consultant Medical Oncologist
Mount Vernon Cancer Centre, Northwood, Middlesex

Metastatic melanoma – biology, immunology and drug discovery combine to transform a lethal disease
4pm Thursday 11th February 2016
Room B1, The Education Centre, RSCH

Metastatic melanoma is usually insensitive to conventional chemotherapy and had a median survival of approximately 9 months. Recent advances in understanding the biology of the disease and the immunological interaction between host and cancer have resulted in the identification and exploitation of new targets that have transformed outcomes for many patients.


View the seminar interview here: https://youtu.be/w5GyBpGjwYU




  Dr Mariam Jamal-Hanjani
Clinical Research Fellow to Professor Charles Swanton
Translational Cancer Therapeutics Laboratory
UCL Cancer Institute and UCL Hospitals

The lung TRACERx study

3pm on Friday 11th December 2015
Room B1, The Education Centre, RSCH

Advances in next-generation sequencing and bioinformatics have led to an unprecedented view of the cancer genome and tumour evolution. Genomic studies have demonstrated the complex and heterogeneous clonal landscape of tumours of different origins, and the potential impact of intratumour heterogeneity on treatment response and resistance. Longitudinal genomic studies that employ tissue and blood sampling can integrate both genomic and clinical data to define the breadth of genetic diversity in cancer and determine its relevance to patient outcome. One such study is TRACERx (TRAcking Cancer Evolution through therapy (Rx)); a prospective study of patients with primary non-small cell lung cancer, which through multi-region genetic sequencing and longitudinal tissue and blood sampling, aims to define the evolutionary pathways of lung cancer from diagnosis to relapse.


View the seminar interview here: https://www.youtube.com/watch?v=V6bhRV4LYXY



  Professor Ian Tomlinson
Professor of Molecular and Population Genetics
Wellcome Trust Centre for Human Genetics
University of Oxford

The ultramutator phenotype in colorectal cancer
4 pm Thursday 12th November 2015
Room B1, The Education Centre, RSCH

Microsatellite instability has been a hallmark of 10-15% of colorectal cancers for over 20 years. These cancers carry a high burden of small mutations and have a good prognosis in stage 2/3 disease. Recently, a group of cancers with an even higher mutation burden has been described. These "ultramutator" cancers carry mutations in DNA polymerase epsilon. In this seminar, Professor Tomlinson will describe the discovery of these cancers, their clinical features and the importance of identifying them amongst the more common types of colorectal carcinoma.


View the seminar interview here: https://youtu.be/NOljoafdhjk



 Professor Tony Ng
Richard Dimbleby Professor of Cancer Research, King's College London and Honorary Professor of Molecular Oncology/Imaging, UCL Cancer Institute

Integrating imaging, genomic and protein network rewiring information to stratify cancer therapy
2pm Monday 5th October 2015
Room B2, The Education Centre, RSCH

Current prognostic/outcome prediction methodologies could be improved by a better understanding of the regulation within the gene and protein networks within a tumour cell. A new concept of protein network rewiring that evolves as a resistance mechanism in human cancer under treatment pressure, has been developed. In the majority of basal-like breast cancer patients who undergo neoadjuvant therapy with cetuximab and panitumumab and still show evidence of residual cancer burden (lack of pathological complete response), tumour cells undergo active rewiring of their ErbB receptors.
Using Fluorescence Lifetime Imaging Microscopy (FLIM) histology techniques, EGFR-HER3 dimerization is observed to occur following EGFR targeted treatment in basal-like breast cancer patients.  This dimerization provides an escape mechanism against molecule-targeted therapies that go beyond cetuximab and panitumumab, to include PI3K/Akt blockade. The therapeutic implication is that this subset of women would benefit from combining cetuximab with anti-HER3 therapy. This rewiring mechanism is also relevant to and therefore being investigated in other tumour groups namely, colorectal, prostate and lung cancers.
There is also a need to combine new whole body molecular imaging techniques (against c-Met, S100A8/A9, etc), and plasma exosomes (proteome and microRNome), to understand and monitor both tumour and microenvironment changes, that influence for instance, lymphatic based metastasis of cancers and the creation of premetastatic lung niche. Innate lymphoid cell-3 (ILC-3) and myeloid-derived suppressor cell-derived exosomes will be presented as respective immunological mechanisms.
As part of the CRUK Lung Cancer Centre of Excellence, we would like to integrate imaging, genomic and protein network rewiring information to stratify treatment. The ultimate objective is to derive and guide future therapies that can overcome primary or acquired resistance and either turn cancer into a chronic disease or achieve cure.




 Professor Johann de Bono
Professor of Experimental Cancer Medicine,
The Institute of Cancer Research and Royal Marsden

Molecularly stratified treatment for lethal prostate cancer
4pm Thursday 17th September 2015
Room B1, The Education Centre, RSCH

This is an unprecedented time of progress in prostate cancer research. Next generation sequencing studies are elucidating the major inter-patient heterogeneity that was recognised by Gleason scoring many years ago and are likely to drive the molecular stratification of this disease in future therapeutic trials. Studies of cancer exomes, genomes and transcriptomes are generating data that will lead to the clinical qualification of critically important predictive biomarkers and most importantly the study of actionable genomic aberrations of pathways including the PI3K/AKT pathway, WNT signalling, DNA repair and RAS/RAF/MEK signalling. It is envisioned that these studies will result in further important key trials and therapeutic developments that will transform outcome from this disease.



 No Seminar - Inaugural Joint Cancer Conference with King’s Health Partners
June 26
University of Surrey

Showcasing advances in cancer research from basic science to clinical application.

Click here for more information.



 Mr Chris Carrigan
Director of the National Cancer Intelligence Network

Is cancer a good model for world class health intelligence?
11am Thursday 7th May 2015
Room B2, The Education Centre, RSCH

We are increasingly an information-led society and, whilst there is much talk about ‘big data’, it is sometimes difficult to see through the rhetoric.  The NHS has so much data and information that it struggles to understand it and yet it demands that ever increasing volumes are collected from clinicians and nurses.
So what is the reality?  What do we do with all this data?  Have we succeeded in just creating a massive ‘data bucket’ or has the cancer community in this country led the way to becoming a world-leader in data, information and intelligence?


View the seminar interview here: https://youtu.be/9ov0xqZ3spE


 Professor Lesley Fallowfield, FMedSci
Brighton and Sussex Medical School
University of Sussex

Why patient reported outcomes matter
2pm Friday 24th April 2015
Room B1, The Education Centre, RSCH

Striking advances in cancer treatment over the past decade have provided many more patients with a genuine prospect of cure or much longer survival with their disease. However there are considerable psychosocial and iatrogenic harms created by both disease and treatment. CTCAE grades used within trials do not always adequately capture quality of life threatening adverse events, so whilst most novel therapies appear initially to have few side effects, it is only with longer term use in community settings that the harms as well as benefits are fully realised. Well validated and reliable patient reported outcomes (PROs) are needed for adequate health technology assessment. Systematic monitoring not only ensures that any ameliorative interventions are made available to individual patients as soon as possible, but also adds to our knowledge about the harms of treatment that require further research into potential amelioration. This talk will provide examples of how valuable PROs can be in both trial and clinic settings.



View the seminar interview here: https://youtu.be/DAsCwGiAvVY


 Dr Adele Francis
Consultant Breast Surgeon, University Hospital Birmingham
Honorary Senior Lecturer in Cancer Sciences, University of Birmingham

Can breast cancer be over treated? How the Sloane Project and LORIS Trial are addressing overtreatment of ductal carcinoma in situ.
2.30pm Thursday 12th March 2015
Room B1, The Education Centre, RSCH

There has been much public debate over the benefits and Harms of Breast Screening. Much of the controversy regards the detection and treatment of Ductal Carcinoma in Situ (DCIS). How is the uncertainty regarding treatment of DCIS being addressed through research?


View the seminar interview here: https://youtu.be/uSTxDEX99d4



 Caterina Marchiò, MD PhD
Assistant Professor of Pathology
Department of Medical Sciences, University of Turin

Facts and artefacts in HER2 study: how recent experimental results may impact on breast cancer diagnostic pathology
2.30pm Monday 2nd February 2015
Room B1, The Education Centre, RSCH

HER2 is overexpressed in about 15% of all breast cancers. This is a direct result of gene amplification in ~95% of cases and represents perhaps the best target for individualised therapy because it has been shown to be a tumour driver and an excellent example of "oncogene addiction". Several anti-HER2 agents are currently available to breast cancer patients, ranging from humanised monoclonal antibodies (trastuzumab and pertuzumab) to tyrosine kinase inhibitors. Correct identification of true HER2 positivity in tissue specimens is a crucial issue as it has such important therapeutic implications. This need is further enhanced by the possibility of delivering trastuzumab as an antibody-drug conjugate (trastuzumab emtansine, T-DM1, Kadcyla) consisting of trastuzumab linked to the cytotoxin mertansine (DM1). In this talk, key factors affecting current HER2 testing will be discussed, including technical issues and interpretational dilemmas.


View the seminar interview here: https://youtu.be/BFPnK1AJIZk


 Professor Rebecca Fitzgerald, MACantab, MD, FRCP, FMedSci
MRC, Cancer Unit, Cambridge

From lab science to practical solutions for earlier diagnosis of oesophageal cancer
3pm Thursday 15th January 2015
Room B1, The Education Centre, RSCH

Professor Fitzgerald heads a diverse multi-disciplinary team whose research focuses on the early detection of oesophageal cancer through better understanding of the molecular pathogenesis. Oesophageal cancers are the 8th most common cancer worldwide and the 6th most common cause of cancer death with only 15% surviving 5 years. Early diagnosis of both main subtypes (adenocarcinoma and squamous cell carcinoma) improves survival dramatically.
Main research aims are to:
Understand the underlying clinical, genetic and cell environmental factors that lead to the conversion of a low-risk pre-malignant state into invasive cancer.
Find new diagnostic tools that will identify those patients who are at an increased risk of developing cancer.
Improve the molecular characterisation of oesophageal adenocarcinoma and identify novel approaches for tumour classification, monitoring and therapy.


View the seminar interview here:https://youtu.be/UmptcyUeXJ0




Professor Arnie Purushotham
King’s College London

Novel intra-operative imaging in breast cancer
1pm Friday 19th December 2014
Room B1, The Education Centre, RSC

A key problem that currently affects the success of breast conserving surgery and sentinel lymph node biopsy (SLNB) is the lack of accurate, real-time techniques to assess tumour margins and SLNs intraoperatively.  As a result, a significant number of patients require additional surgery to obtain clear margins and/or undergo completion axillary lymph node dissection for a positive SLN. Terahertz (THz) imaging and Cerenkov Luminescence Imaging (CLI) are two novel imaging techniques that have the potential to address this need. Two first-in-(wo)man studies are currently being conducted by Professor Purushotham and his research team to evaluate the performance of these techniques for tumour margin and SLN assessment in breast cancer surgery. In this seminar Professor Purushotham will address the principles of THz imaging and CLI and will show some of the preliminary results.





 Professor Tim Maughan
CRUK/MRC Oxford Institute for Radiation Oncology
Gray Laboratories
University of Oxford

Curing the hard to treat cancers, a new vision for cancer research
Friday 7th November 2014
Room B1, The Education Centre, RSCH




Dr Nick Orr
Institute of Cancer Research

Germline susceptibility to breast cancer
3.30pm Thursday 23rd October 2014
Room B1, The Education Centre, RSCH

In the past decade genetic epidemiological studies have uncovered hundreds of germline determinants of common complex diseases, including breast cancer. However there is a perception that initial discoveries have been slow to translate into patient benefit. In this seminar I’ll provide an overview of genetic susceptibility to breast cancer and discuss potential applications in stratified prevention, along with recent insights into the underlying biology of genetic susceptibility to breast cancer that have arisen from large scale breast cancer association studies



Professor Martin Glennie
University of Southampton

Turning the immune system against cancer
2pm Friday 19th September 2014
Room B1, The Education Centre, RSCH

Monoclonal antibodies which promote T-cell responses are proving highly effective in cancer treatment, with increasing evidence that such responses can be harnessed to provide durable eradication of tumours.  Results with anti-CTLA-4 (cytotoxic T-lymphocyte antigen 4), anti-CD40 and anti-PD-1 (programmed death 1) mAb have reinforced the view that T-cell immunity can provide long-lasting protection against aggressive and difficult to treat cancers, such as metastatic melanoma and non-small cell lung cancer.  In this lecture we will discuss these results and the various mechanisms of action which have been proposed to explain how such mAb work and how their activity can be improved by Ab engineering.